Suggested remit: To appraise the clinical and cost effectiveness of avatrombopag within its marketing authorisation for treating chemotherapy-induced thrombocytopenia in non-haematological cancers.
 
Status Awaiting development
Process STA Review
ID number 3837

Project Team

Project lead Michelle Adhemar

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
03 February 2021 - 03 March 2021 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators
17 February 2021 The National Institute for Health and Care Excellence (NICE) has been asked to conduct an appraisal of avatrombopag for treating chemotherapy-induced thrombocytopenia in non-haematological cancers. We have recently invited stakeholders to respond to a written consultation on the draft scope for this appraisal. The company that market avatrombopag has advised NICE that they are currently not pursuing a licence in the UK for this product for this indication. In light of this information, NICE will not be progressing with the scoping exercise. The consultation on the draft scope will now close. Please accept our apologies for any inconvenience.

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance